Boehringer Ingelheim

Boehringer Ingelheim

INGELHEIM, Germany
Pharmaceutical3 H-1B visas (FY2023)
WebsiteLinkedInCareers Page

Focus: Small Molecules, Biologics

Boehringer Ingelheim is a life sciences company focused on Small Molecules, Biologics.

RespiratoryOncologyCardiovascularImmunologyNeuroscience
Funding Stage
PRIVATE
Employees
53,000
Open Jobs
0

Products & Portfolio (26)

24 discontinued products not shown

APTIVUS
tipranavir
LOE Approaching
ORAL · CAPSULE
HIV Protease Inhibitors
hepatitis B
2005
30
APTIVUS
tipranavir
LOE Approaching
ORAL · SOLUTION
12.1 Mechanism of Action Tipranavir is an antiretroviral drug [ see ]. 12.2 Pharmacodynamics ECG Evaluation The effect of APTIVUS/ritonavir on the QTcF interval was measured in a study in which 81 healthy subjects received the following treatments twice daily for 2.5 days: APTIVUS/ritonavir (500 mg/200 mg), APTIVUS/ritonavir at a supra-therapeutic dose (750 mg/200 mg), and placebo/ritonavir (-/200 mg). After baseline and placebo adjustment, the maximum mean QTcF change was 3.2 ms (1-sided 95% Upper CI: 5.6 ms) for the 500 mg/200 mg dose and 8.3 ms (1-sided 95% Upper CI: 10.9 ms) for the supra-therapeutic 750 mg/200 mg dose. Antiviral Activity in vivo The median Inhibitory Quotient (IQ) determined from 264 treatment-experienced adult subjects was about 80 (inter-quartile range: 31-226), from the controlled clinical trials 1182.12 and 1182.48. The IQ is defined as the tipranavir trough concentration divided by the viral EC 50 value, corrected for protein binding. There was a relationship between the proportion of subjects with a ≥1 log 10 reduction of viral load from baseline at week 48 and their IQ value. Among the 198 subjects receiving APTIVUS/ritonavir with no new enfuvirtide use (e.g., new enfuvirtide, defined as initiation of enfuvirtide for the first time), the response rate was 23% in those with an IQ value <80 and 59% in those with an IQ value ≥80. Among the 66 subjects receiving APTIVUS/ritonavir with new enfuvirtide, the response rates in subjects with an IQ value <80 versus those with an IQ value ≥80 were 55% and 71%, respectively. These IQ groups are derived from a select population and are not meant to represent clinical breakpoints. 12.3 Pharmacokinetics In order to achieve effective tipranavir plasma concentrations and a twice-daily dosing regimen, co-administration of APTIVUS with ritonavir is essential [ see ]. Ritonavir inhibits hepatic cytochrome P450 3A (CYP3A), the intestinal P-gp efflux pump and possibly intestinal CYP3A. In a dose-ranging evaluation in 113 HIV-1 negative male and female volunteers, there was a 29-fold increase in the geometric mean morning steady-state trough plasma concentrations of tipranavir following APTIVUS co-administered with low-dose ritonavir (500 mg/200 mg twice daily) compared to APTIVUS 500 mg twice daily without ritonavir. In adults the mean systemic ritonavir concentration when 200 mg of ritonavir was given with 500 mg of APTIVUS was similar to the concentrations observed when 100 mg was given with the other protease inhibitors. Figure 1 displays mean plasma concentrations of tipranavir and ritonavir at steady state for 30 HIV-1 infected adult subjects dosed with 500 mg/200 mg tipranavir/ritonavir for 14 days. Figure 1 Mean Steady State Tipranavir Plasma Concentrations (95% CI) with Ritonavir Co-administration (tipranavir/ritonavir 500 mg/200 mg BID) Figure 1 Absorption and Bioavailability Absorption of tipranavir in humans is limited, although no absolute quantification of absorption is availa
hepatitis B
2008
30
ATROVENT HFA
ipratropium bromide
Peak
INHALATION · AEROSOL, METERED
(parasympatholytic) agent which, based on animal studies, appears to inhibit vagally-mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released at the neuromuscular junctions in the lung. Anticholinergics prevent the increases in intracellular concentration of Ca++ which is caused by interaction of acetylcholine with the muscarinic receptors on bronchial smooth muscle.
COPDchronic obstructive pulmonary disease
2004
8
COMBIVENT RESPIMAT
ipratropium bromide and albuterol
Peak
INHALATION · SPRAY, METERED
RESPIMAT: COMBIVENT RESPIMAT is a combination of the anticholinergic ipratropium bromide and the beta 2 -adrenergic agonist albuterol sulfate. The mechanisms of action described below for the individual components apply to COMBIVENT RESPIMAT. The two classes of medications (an anticholinergic and a beta 2 -adrenergic agonist) are both bronchodilators. Simultaneous administration of both an anticholinergic (ipratropium bromide) and a beta 2 -sympathomimetic (albuterol sulfate) is designed to produce a greater bronchodilator effect than when either drug is utilized alone at its recommended dosage. The efficacy of COMBIVENT RESPIMAT is likely to be due to a local effect on the muscarinic and beta 2 -adrenergic receptors in the lung. Ipratropium bromide Ipratropium bromide is an anticholinergic (parasympatholytic) agent which, based on animal studies, appears to inhibit vagally mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released at the neuromuscular junctions in the lung. Anticholinergics prevent the increases in intracellular concentration of Ca++ which is caused by interaction of acetylcholine with the muscarinic receptors on bronchial smooth muscle. Albuterol sulfate In vitro studies and in vivo pharmacology studies have demonstrated that albuterol has a preferential effect on beta 2 -adrenergic receptors compared with isoproterenol. While it is recognized that beta 2 -adrenergic receptors are the predominant receptors on bronchial smooth muscle, recent data indicate that there is a population of beta 2 -receptors in the human heart which comprise between 10% and 50% of cardiac beta-adrenergic receptors. The precise function of these receptors, however, is not yet established [ see Warnings and Precautions ]. Activation of beta 2 -adrenergic receptors on airway smooth muscle leads to the activation of adenylyl cyclase and to an increase in the intracellular concentration of cyclic-3',5'-adenosine monophosphate (cyclic AMP). This increase of cyclic AMP leads to the activation of protein kinase, which inhibits the phosphorylation of myosin and lowers intracellular ionic calcium concentrations, resulting in relaxation. Albuterol relaxes the smooth muscles of all airways, from the trachea to the terminal bronchioles. Albuterol acts as a functional antagonist to relax the airway irrespective of the spasmogen involved, thus protecting against all bronchoconstrictor challenges. Increased cyclic AMP concentrations are also associated with the inhibition of release of mediators from mast cells in the airway. Albuterol has been shown in most clinical trials to have more bronchial smooth muscle relaxation effect than isoproterenol at comparable doses while producing fewer cardiovascular effects. However, all beta‑adrenergic agonist drugs, including albuterol sulfate, can produce a significant cardiovascular effect in some patients [ see Warnings and Precautions ].
chronic obstructive pulmonary diseaseCOPD
2011
8
CYLTEZO
adalimumab-adbm
Peak
mAbINJECTION · INJECTABLE
TNF-alpha and block its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab products also lyse surface TNF expressing cells in vitro in the presence of complement. Adalimumab products do not bind or inactivate lymphotoxin (TNF-beta). TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Elevated concentrations of TNF are found in the synovial fluid of patients with RA, JIA, PsA, and AS and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of these diseases. Increased concentrations of TNF are also found in psoriasis plaques. In Ps, treatment with Adalimumab-adbm may reduce the epidermal thickness and infiltration of inflammatory cells. The relationship between these pharmacodynamic activities and the mechanism(s) by which adalimumab products exert their clinical effects is unknown. Adalimumab products also modulate biological responses that are induced or regulated by TNF, including changes in the concentrations of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC 50 of 1-2 × 10M).
moderately to severely active Crohn's disease in adultsoldermoderately to severely active ulcerative colitis in adult patients+10 more
2017
30
GILOTRIF
afatinib
Peak
ORAL · TABLET
Protein Kinase Inhibitors
2013
8
GLYXAMBI
empagliflozin and linagliptin
Peak
ORAL · TABLET
Dipeptidyl Peptidase 4 Inhibitors
2015
0
HERNEXEOS
zongertinib
Launch
ORAL · TABLET
HER2/Neu/cerbB2 Antagonists
2025
0
JARDIANCE
empagliflozin
Peak
ORAL · TABLET
Sodium-Glucose Transporter 2 Inhibitors
2014
0
JASCAYD
nerandomilast
Launch
ORAL · TABLET
4 (PDE4) with at least nine-fold preferential inhibition of the PDE4B isoenzyme over PDE4A, PDE4C, and PDE4D based on in vitro data. PDE4 hydrolyzes and inactivates cyclic adenosine monophosphate (cAMP). Nerandomilast exerts both antifibrotic and immunomodulatory effects as PDE4B inhibition elevates intracellular cAMP levels and reduces the expression of profibrotic growth factors and inflammatory cytokines, which are overexpressed in IPF and PPF.
idiopathic pulmonary fibrosis (IPF) in adult patientsprogressive pulmonary fibrosis (PPF) in adult patients
2025
0
JASCAYD
nerandomilast
Launch
ORAL · TABLET
2025
30
JENTADUETO
linagliptin and metformin hydrochloride
Peak
ORAL · TABLET
Dipeptidyl Peptidase 4 Inhibitors
2012
0
View all 26 products

Pipeline & Clinical Trials

Impact of Ramadan on Achieving Joint National Committee (JNC) 7 Treatment Goals in CV Risk Patients
Hypertension
N/A
Clinical Trials (1)
NCT01853839Impact of Ramadan on Achieving Joint National Committee (JNC) 7 Treatment Goals in CV Risk Patients
N/A
Olodaterol/Tiotropium Bromide
Pulmonary Disease, Chronic Obstructive
N/A
Clinical Trials (1)
NCT03979807A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD)
N/A
expert support for interpretation of spirometry
Pulmonary Disease, Chronic Obstructive
N/A
Clinical Trials (1)
NCT00131157Evaluation of Spirometry Expert Support in General Practice
N/A
Cymbalta
Pain
N/A
Clinical Trials (1)
NCT02215798Post-Marketing Surveillance Study on the Safety and Efficacy of Cymbalta (Duloxetine) on Diabetic Peripheral Neuropathic Pain Among Filipino Patients
N/A
N/A
Clinical Trials (1)
NCT05701176A Clinical Imaging Study of the Changes in [18F]F-AraG Uptake Following Anti-PD-1 Therapy in Non-small Cell Lung Cancer
N/A
N/A
Clinical Trials (2)
NCT07472517DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy
Phase 3
NCT02215733The Use of Angiotensin Receptor Blockers and the Risk of Cancer
N/A
N/A
Clinical Trials (1)
NCT03064841Clinical Characteristics, Anti-hyperglycaemic Treatment Pattern and Target Attainment of Type 2 Diabetes Mellitus Patients in Older Population With or Without Albuminuria in China
N/A
N/A
Clinical Trials (1)
NCT04249310Early Intervention Efficacy in COPD
N/A
N/A
Clinical Trials (1)
NCT05151640INCHANGE - Nintedanib for Changes in Cough and Dyspnea in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation
N/A
Integrative-omics of the Disordered COPD Small Airway Epithelium
Smoking
N/A
Clinical Trials (1)
NCT02183818Integrative-omics of the Disordered COPD Small Airway Epithelium
N/A
No intervention.
Parkinson's Disease
N/A
Clinical Trials (1)
NCT00804479The Long Term Impact of Initiating Pramipexole Versus Levodopa in Early Parkinson's Disease (CALM-PD Cohort Study)
N/A
N/A
Clinical Trials (1)
NCT03843892An Expanded Access Program to Provide Nintedanib to Patients With Non-IPF ILD Who Have no Alternative Treatment Possibilities
N/A
LABA and the LAMA tiotropium
Pulmonary Disease, Chronic Obstructive
N/A
Clinical Trials (1)
NCT03376295Comparative Effectiveness of COPD Treatments
N/A
Comprehensive non invasive cardiovascular examination
Coronary Heart Disease
N/A
N/A
Clinical Trials (1)
NCT02172482Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
N/A
N/A
Clinical Trials (1)
NCT03457935Detection of Early Idiopathic Pulmonary Fibrosis
N/A
An Observational Cohort Study to Evaluate the Safety and Efficacy of Micardis Tablets Taken Once Dai
Hypertension
N/A
Clinical Trials (1)
NCT00982735An Observational Cohort Study to Evaluate the Safety and Efficacy of Micardis Tablets Taken Once Daily at 40 mg/Day and 80 mg/Day in Hypertensive Patients Under Real Life Conditions in Usual Clinical Practice
N/A
Tipranavir
HIV Infections
N/A
Clinical Trials (1)
NCT00976950A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Aptivus Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.
N/A
Clinical Learning Study smartphone app
Schizophrenia
N/A
Clinical Trials (1)
NCT05438160Exploratory Study of a Digital Therapeutics in People With Schizophrenia
N/A
Describing Patient With DME, Their Patient Journey and Disease Progression
Diabetic Macular Edema
N/A
Clinical Trials (1)
NCT05966753Describing Patient With DME, Their Patient Journey and Disease Progression
N/A
N/A
Clinical Trials (1)
NCT04559581Post-marketing Surveillance of Ofev Capsules in Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype in Japan
N/A
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Venous Thromboembolism
N/A
Clinical Trials (1)
NCT02596230RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
N/A
Non-interventional Observational Study With Viramune (Nevirapine) and Various Drug Combinations in t
HIV Infections
N/A
Clinical Trials (1)
NCT00979420Non-interventional Observational Study With Viramune (Nevirapine) and Various Drug Combinations in the Antiretroviral Combination Treatment of HIV-infected Patients Who Have Already Been Treated for Approx. 10 Years With Viramune
N/A
N/A
Clinical Trials (1)
NCT02238145Postmarketing Surveillance Study of Atrovent® Inhaletten® in Chronic Obstructive Airways Disease
N/A
Rosuvastatin
Liver Cirrhosis
N/A
Clinical Trials (1)
NCT05741372A Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosis
N/A
Viramune®
HIV Infections
N/A
Clinical Trials (1)
NCT02191319Observational Study With Antiretroviral Treated Patients Switching to Nevirapine Plus Two Nucleoside Reverse Transcriptase Inhibitor (NRTI) Regimens
N/A
N/A
Clinical Trials (1)
NCT03464045Empa PASS on Urinary Tract Malignancies
N/A
N/A
Clinical Trials (1)
NCT02755181fMRI in Impulsivity
N/A
Non-vitamin K antagonist oral anticoagulant
Atrial Fibrillation
N/A
Clinical Trials (1)
NCT03993119This Study Observes the Usage of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) in Elderly Patients With a Heart Rhythm Disorder in Spain
N/A
Micardis®
Hypertension
N/A
Clinical Trials (1)
NCT02242864Study to Evaluate the Effect of the Treatment With Micardis® or MicardisPlus® on Blood Pressure
N/A
Oxygen Therapy Use in Patients With Fibrotic Interstitial Lung Disease
Lung Diseases, Interstitial
N/A
Clinical Trials (1)
NCT05957198Oxygen Therapy Use in Patients With Fibrotic Interstitial Lung Disease
N/A
N/A
Clinical Trials (1)
NCT04909073Observational Study of Afatinib 30 mg Daily
N/A
Dabigatran etexilate
Atrial Fibrillation
N/A
Clinical Trials (1)
NCT03006341Validation of Predictors of OAC Initiation Using EMR Data
N/A
Patients With Geographic Atrophy and Their Patient Journey in the United States (US)
Geographic Atrophy
N/A
Clinical Trials (1)
NCT05891275Patients With Geographic Atrophy and Their Patient Journey in the United States (US)
N/A
A Study Based on Health Insurance Data About the Treatment of Patients Who Have Been Newly Diagnosed
Pulmonary Disease, Chronic Obstructive
N/A
Clinical Trials (1)
NCT04097223A Study Based on Health Insurance Data About the Treatment of Patients Who Have Been Newly Diagnosed With Chronic Obstructive Pulmonary Disease (COPD)
N/A
N/A
Clinical Trials (1)
NCT02172560A Collection of Vital Status and Pulmonary Medication Usage Data for Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Withdrew Prematurely From Tiotropium Inhalation Solution Delivered by the Respimat Inhaler
N/A
N/A
Clinical Trials (1)
NCT02367131Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus
N/A
Use of Synvisc® in Knee Osteoarthritis - Medico-economical Study
Osteoarthritis
N/A
Clinical Trials (1)
NCT02195505Use of Synvisc® in Knee Osteoarthritis - Medico-economical Study
N/A
Tipranavir
HIV Infections
N/A
Clinical Trials (1)
NCT00062660Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection
N/A
N/A
Clinical Trials (1)
NCT02285361GIOTRIF rPMS in Korean Patients With NSCLC
N/A
Viramune® tablets
HIV Infections
N/A
Clinical Trials (1)
NCT02191293Long-term Study in Patients Under Anti-retroviral Combination Therapy Switching to Viramune®
N/A
Empagliflozin
Heart Failure
N/A
Clinical Trials (1)
NCT05350202Emp-Activity: Empagliflozin Functional Capacity
N/A
N/A
Clinical Trials (1)
NCT04098575A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes
N/A
Treatment Convenience in Patients Treated With Dabigatran for Stroke Prophylaxis in Atrial Fibrillat
Atrial Fibrillation
N/A
Clinical Trials (1)
NCT02839746Treatment Convenience in Patients Treated With Dabigatran for Stroke Prophylaxis in Atrial Fibrillation (SPAF)
N/A
Rheumatoid Arthritis-Associated Interstitial Lung Disease: Characterization of Lung Disease Progress
Rheumatoid Lung
N/A
Clinical Trials (1)
NCT04136223Rheumatoid Arthritis-Associated Interstitial Lung Disease: Characterization of Lung Disease Progression
N/A
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
N/A
Clinical Trials (1)
NCT01915511Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
N/A
Long- and intermediate- acting insulins
Diabetes
N/A
Clinical Trials (1)
NCT02922179Descriptive Analysis of Long- and Intermediate-Acting Insulin in Adult Diabetics
N/A
MicardisPlus®
Hypertension
N/A
Clinical Trials (1)
NCT02243566Post-marketing Surveillance Study With MicardisPlus® in Treatment of Morning Hypertension (Self-monitored by Patient)
N/A
Kinetic Tremor in Parkinsons Disease: Its Course Under Pramipexole (Mirapexin®) Treatment and Impact
Parkinson Disease
N/A
Clinical Trials (1)
NCT01100073Kinetic Tremor in Parkinsons Disease: Its Course Under Pramipexole (Mirapexin®) Treatment and Impact on Quality of Life
N/A
There are no interventions in this study. All participants complete online surveys.
Lung Cancer Patients
N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 57 approved products, 149 clinical trials
Top TAs: Respiratory, Oncology, Cardiovascular
H-1B (2023): 3 approvals
Publications: 25 in PubMed
Portfolio Health
Pre-Launch2 (4%)
Launch3 (5%)
Peak21 (37%)
LOE Approaching29 (51%)
Post-LOE2 (4%)
57 total products
Therapeutic Area Focus
Respiratory
14 marketed437 pipeline
Oncology
2 marketed327 pipeline
Cardiovascular
5 marketed231 pipeline
Metabolic Diseases
8 marketed198 pipeline
Infectious Diseases
3 marketed123 pipeline
Neurology
2 marketed122 pipeline
Immunology
3 marketed70 pipeline
Nephrology
53 pipeline
Marketed
Pipeline

Visa Sponsorship

Sponsors Work Visas
H-1B Petitions (FY2023)
3
Approved
0
Denied
100%
Rate

Source: USCIS H-1B Employer Data Hub